Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 16:04Monia Ezzalfani: Advancing Patient-Centered Care in Hemophilia A and B
-
Sep 23, 2026, 15:49Bilge Başak: How Activated PRP Modulates Osteoarthritic Chondrocyte Function
-
Sep 23, 2026, 14:50Mbonjo Bitsie Dora: Strengthening Sickle Cell Care Through Education, Awareness and Innovation
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology